Agios Pharmaceuticals recently presented the first data from its Phase 1 AG-120 study dose expansion cohorts at the Society for Neuro-Oncology (SNO) annual meeting.
“Glioma and chondrosarcomas are extremely difficult-to-treat diseases where patients are in need of new therapies,” Agios Chief Medical Officer Dr. Chris Bowden said. “These Phase 1 dose expansion data are encouraging, as they continue to demonstrate a well-tolerated safety profile for AG-120 at a fixed daily dose of 500 mg. The prolonged stable disease in both patient populations is encouraging in light of AG-120’s unique differentiation mechanism of action.”
The Phase 1 study is evaluating the safety and patient tolerability of AG-120 in advanced solid tumors. This includes glioma, intrahepatic cholangiocarcinoma.
“In glioma, AG-120 has the potential to help a large number of patients with IDH1 mutations,” Dr. Ingo Mellinghoff, an investigator for the study. “The SNO presentation is the first look at data for AG-120 in a defined cohort of glioma patients where we evaluated the potential for volumetric analyses to improve our understanding of the response patterns beyond the conventional bi-dimensional methods. This methodology could be instrumental in developing more effective, targeted therapies for patients with this disease.”